

REMARKS

Claims 1, 3, 4, 6 to 8, 11 to 18, 22, 24, 26 and 27 are present.

Claims 19, 20 and 21 have been cancelled.

Claims 21 and 22 are rejected under 35 U.S.C. §112, first paragraph.

Claims 1, 3, 4, 6 to 8, 11 to 18, 24, 26 and 27 are allowed.

Amendments

Claim 22 has been amended so that it no longer depends from Claim 21.

Claim 16 has been amended as suggested by the Examiner to replace "x¹" in the formula with --y-- so that it is consistent with Claim 14.

Claims 21 and 22 are rejected under 35 U.S.C. §112, first paragraph.

Claim 21 has been cancelled.

Claim 22 is directed to a method of using the compounds of Claim 1 to treat certain inflammatory or immune diseases. As indicated on pages 1 to 4 of the Specification, it is known in the art that melanocortin-receptor agonists are known for treating MC-1R or MC-4R associated conditions as claimed in Claim 22. Applicants include compositions, dosages and methods of treating the diseases of Claim 22 and therefore provide an enabling disclosure.

It is therefore believed that Claim 22 complies with 35 U.S.C. §112, first paragraph.

Summary

In view of the foregoing the Applicants believe that Claims 1, 3, 4, 6 to 8, 11 to 18, 22, 24, 26 and 27, as amended, are now in condition for allowance.


The Examiner is invited to contact the undersigned by telephone, at the number listed below, if it is believed that a telephonic communication would facilitate the prosecution of this application.

Fees

If it is determined that a fee is due, please charge same to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-4336



Burton Rodney
Attorney for Applicants
Reg. No. 22,076

Date: *February 14, 2005*